QUANTA-CLOUD-TECHNOLOGY
26.7.2022 05:53:13 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced the world’s first validation of Samsung PM1743 PCIe Gen5 SSDs in their new all-flash NVMe™ servers powered by 4th Gen Intel® Xeon® Scalable processors. 4th Gen Intel Xeon Scalable processors will deliver substantial compute performance across traditional data center usages with unique purpose-built workload optimizations for today’s edge to cloud models. These technology updates in QCT’s growing line of QuantaGrid servers add additional performance for Samsung’s high-bandwidth flash storage due to the 4th Gen Intel Xeon Scalable processors support of leading industry standard technologies such as DDR5, Intel® Optane™ persistent memory, and PCIe Gen5. Furthermore, these unique solutions provide flexibility for modern data center needs ranging from low latency applications to data processing, and hyper-converged infrastructures (HCI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005386/en/
To accommodate the rapidly increasing performance requirements of data centers, PCIe Gen5 doubles IOPS per watt and throughput compared to the previous generation. Samsung’s PM1743 SSD for enterprise servers integrates the PCIe Gen5 interface with Samsung’s advanced sixth-generation V-NAND to deliver 30% enhanced power efficiency than the previous generation, resulting in lower server operating costs and increasing scalability for virtualized environments like HCI and software-defined storage.
With the evolution of data centers to the rapid growth of data and proliferation of applications that demand high performance, QCT’s upcoming QuantaGrid series offer flexibility for scaling out with Samsung’s new storage innovation. The QuantaGrid D54X-1U and D54Q-2U are designed for dual 4th Gen Intel Xeon Scalable processors with 32 DDR5 DIMM slots and support for Intel Optane persistent memory, which provides affordable memory capacity expansion and support for data persistence. The two servers mainly differ in storage capacity and number of expansion slots that will be further revealed with the release of 4th Gen Intel Xeon Scalable processors.
“QCT worked closely with Samsung to test and be among the first to validate Samsung’s PM1743 PCIe Gen5 SSDs on our Intel powered systems,” said Mike Yang, President of QCT. “Together with Samsung, and Intel, our technology leadership will continue to drive new applications as we accelerate the growth of the server market and deliver unparalleled performance advantages for IOPS-intensive applications.”
"Samsung has been working closely with QCT and Intel to show PCIe Gen5 PM1743 SSDs provide optimized performance for all-flash NVMe workloads in their QuantaGrid 1U and 2U systems," said Yongcheol Bae, Executive Vice President of the Memory Application Engineering Team at Samsung Electronics. “Collectively, with the introduction of our PCIe Gen5 SSD, Intel’s 4th Gen Xeon Scalable processors, and QCT’s QuantaGrid server line we will further solidify our technological leadership in the enterprise server market.”
“Our goal is to deliver industry leadership to accelerate data center performance and user experiences with our upcoming 4th Gen Intel Xeon Scalable processors,” said Zane Ball, Intel Corporate Vice President and General Manager of Data Platforms Engineering and Architecture. “The collaboration with QCT and Samsung signifies Intel’s commitment to providing our customers with a multitude of ways to enhance their applications with high-speed NVMe SSDs that enable deployments from edge to cloud.”
Follow QCT on Facebook and Twitter to receive their latest news and announcements.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About QCT
QCT is a global datacenter solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. www.QCT.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005386/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom